Y1968
2021-06-11
Support liao
ORPH Stock: Is There a Big Orphazyme Catalyst on June 17?
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":181051191,"tweetId":"181051191","gmtCreate":1623368518813,"gmtModify":1634034206518,"author":{"id":3581727244675977,"idStr":"3581727244675977","authorId":3581727244675977,"authorIdStr":"3581727244675977","name":"Y1968","avatar":"https://static.tigerbbs.com/f6a22f88deb287b757cb3e60419d2882","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":29,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Support liao</p></body></html>","htmlText":"<html><head></head><body><p>Support liao</p></body></html>","text":"Support liao","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/181051191","repostId":1141539721,"repostType":4,"repost":{"id":"1141539721","kind":"news","pubTimestamp":1623367933,"share":"https://www.laohu8.com/m/news/1141539721?lang=&edition=full","pubTime":"2021-06-11 07:32","market":"us","language":"en","title":"ORPH Stock: Is There a Big Orphazyme Catalyst on June 17?","url":"https://stock-news.laohu8.com/highlight/detail?id=1141539721","media":"investorplace","summary":"Today, Orphazyme(NASDAQ:ORPH) is a big mover. And by big mover, I mean ORPH stock is up nearly 1,000","content":"<p>Today, <b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is a big mover. And by big mover, I mean ORPH stock is up nearly 1,000% at the time of writing.</p>\n<p>This is a stock that closed yesterday trading at $5.22. At the time of writing, shares of ORPH stock are trading in excess of $56.</p>\n<p>Obviously, something is cooking with this stock right now. And investors seem to be asking what the heck is going on. A series of halts this morning, and immediate pops following the halts, have triggeredspeculationsome sort of manipulation is occurring.</p>\n<p>In the absence of any real news, let’s take a look at what this company does, and what sort of catalysts investors (might) be banking on with this stock.</p>\n<p><b>What Is Orphazyme Stock All About?</b></p>\n<ul>\n <li>Orphazymeis a late-stage biopharma company specializing in pioneering a heat-shock protein response for the treatment of neurodegenerative orphan diseases.</li>\n <li>Accordingly, the company aims to harness the amplification of heat-shock proteins to develop and commercialize novel therapeutics.</li>\n <li>The company’s leading drug candidate is arimoclomol.</li>\n <li>This drug is in clinical development targeted at four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis (IBM) and Gaucher disease.</li>\n <li>Orphazyme is based out of Denmark, and its shares are listed in the U.S. on the<b>Nasdaq</b>as an American Depositary Receipt.</li>\n <li>This company’s operations mainly focus in Europe, but it also has operations in the United States.</li>\n <li>Orphazyme stock briefly touched anall-time highof $77.77 today, giving this company a market cap of $2.7 billion at its peak.</li>\n</ul>\n<p><b>ORPH Stock Soaring on Little News</b></p>\n<p>Despite today’s move on what appears to be no real catalysts, there are some noteworthy items for investors to consider with ORPH stock.</p>\n<p>The main catalyst investors appear to have their radar is anFDA extended review periodfor the company’s arimoclomol treatment, which expires June 17. Investors have taken to social media to chatabout the PDUFA date as a binary event. This price action could be an indication some good news is on the horizon. However, in the absence of any publicly available information, investors need to be extremely cautious.</p>\n<p>The company’s arimoclomol drug is aimed at the treatment of Niemann-Pick Disease Type C (NPC). This is a rare disease, and the drug remains under the priority review designation by the FDA. Indeed, if some positive news arises to warrant this rise, investors may wonder how this stock rose so quickly ahead of the news.</p>\n<p>For now, investors are left scratching their heads with this one. This is a stock I’ve added to my watch list, and I suggest investors do the same. It will be an intriguing one to watch.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: Is There a Big Orphazyme Catalyst on June 17?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: Is There a Big Orphazyme Catalyst on June 17?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 07:32 GMT+8 <a href=https://investorplace.com/2021/06/orph-stock-is-there-a-big-orphazyme-catalyst-on-june-17/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, Orphazyme(NASDAQ:ORPH) is a big mover. And by big mover, I mean ORPH stock is up nearly 1,000% at the time of writing.\nThis is a stock that closed yesterday trading at $5.22. At the time of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-is-there-a-big-orphazyme-catalyst-on-june-17/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-is-there-a-big-orphazyme-catalyst-on-june-17/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141539721","content_text":"Today, Orphazyme(NASDAQ:ORPH) is a big mover. And by big mover, I mean ORPH stock is up nearly 1,000% at the time of writing.\nThis is a stock that closed yesterday trading at $5.22. At the time of writing, shares of ORPH stock are trading in excess of $56.\nObviously, something is cooking with this stock right now. And investors seem to be asking what the heck is going on. A series of halts this morning, and immediate pops following the halts, have triggeredspeculationsome sort of manipulation is occurring.\nIn the absence of any real news, let’s take a look at what this company does, and what sort of catalysts investors (might) be banking on with this stock.\nWhat Is Orphazyme Stock All About?\n\nOrphazymeis a late-stage biopharma company specializing in pioneering a heat-shock protein response for the treatment of neurodegenerative orphan diseases.\nAccordingly, the company aims to harness the amplification of heat-shock proteins to develop and commercialize novel therapeutics.\nThe company’s leading drug candidate is arimoclomol.\nThis drug is in clinical development targeted at four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis (IBM) and Gaucher disease.\nOrphazyme is based out of Denmark, and its shares are listed in the U.S. on theNasdaqas an American Depositary Receipt.\nThis company’s operations mainly focus in Europe, but it also has operations in the United States.\nOrphazyme stock briefly touched anall-time highof $77.77 today, giving this company a market cap of $2.7 billion at its peak.\n\nORPH Stock Soaring on Little News\nDespite today’s move on what appears to be no real catalysts, there are some noteworthy items for investors to consider with ORPH stock.\nThe main catalyst investors appear to have their radar is anFDA extended review periodfor the company’s arimoclomol treatment, which expires June 17. Investors have taken to social media to chatabout the PDUFA date as a binary event. This price action could be an indication some good news is on the horizon. However, in the absence of any publicly available information, investors need to be extremely cautious.\nThe company’s arimoclomol drug is aimed at the treatment of Niemann-Pick Disease Type C (NPC). This is a rare disease, and the drug remains under the priority review designation by the FDA. Indeed, if some positive news arises to warrant this rise, investors may wonder how this stock rose so quickly ahead of the news.\nFor now, investors are left scratching their heads with this one. This is a stock I’ve added to my watch list, and I suggest investors do the same. It will be an intriguing one to watch.","news_type":1},"isVote":1,"tweetType":1,"viewCount":178,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/181051191"}
精彩评论